Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on November 15, 2006
J Am Soc Nephrol 17: 3273-3275, 2006
© 2006 American Society of Nephrology
doi: 10.1681/ASN.2006101138
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2006101138v1
17/12/3273    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, K. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, K. D.
Related Collections
Right arrowRelated Article

Editorials

Lupus Nephritis: Toll the Trigger!

Kelly D. Smith

Department of Pathology, University of Washington, Seattle, Washington

Address correspondence to: Dr. Kelly D. Smith, Box 356100, 1959 NE Pacific Street, Seattle, WA 98195. Phone: 206-543-0820; Fax: 206-598-4928; E-mail: kelsmith{at}u.washington.edu


   Introduction
Top
 Introduction
Why Nuclear Autoantigens?
 Infectious Triggers to...
 Conclusion
 References
 
Systemic lupus erythematosus (SLE) is an autoimmune disorder that is characterized by the development of autoantibodies against nuclear antigens. These autoantibodies and their cognate antigens form immune complexes that are deposited in the kidneys, lungs, cerebrovasculature, serosal surfaces, and skin, leading to the active and chronic sequelae of this disease. In the past several years, elucidation of the immunologic mechanisms that drive this peculiar autoantibody response has been aided by studies in innate immunity and in particular the Toll-like receptors (TLR). In the current issue of JASN, Pawar et al. (1) provide exciting data that activation of the innate immune system with a specific nucleic acid agonist for TLR-9 induces lupus nephritis in genetically predisposed mice. These data further strengthen the emergence of the innate immune system as a central player in inducing autoimmunity, specifying the nature of the autoantibody response, and regulating the inflammatory activity in the target organs of SLE.


   Why Nuclear Autoantigens?
Top
 Introduction
 Why Nuclear Autoantigens?
Infectious Triggers to...
 Conclusion
 References
 
Several recent studies have shed light on the antigen specificity of the SLE autoantibody response that characterizes SLE. The SLE autoantigens, which include double- or single-stranded DNA (ssDNA), histones, chromatin, and ribonucleoproteins such as Smith antigen, are composed of or intimately associated with nucleic acids. Nucleic acid recognition is a prime strategy for the innate immune system’s detection of microbial pathogens, especially viral pathogens (2,3). The Toll-like receptor family of innate immune receptors is the best characterized and has four receptors that are capable of recognizing nucleic acid ligands: TLR-3 recognizes double-stranded RNA (dsRNA); TLR-7 and TLR-8 recognize ssRNA; and TLR-9 recognizes CpG rich, unmethylated DNA (4). All of these receptors require endocytosis of their ligands for proper recognition, and it is thought that microbial pathogen specificity is determined by the combination of requirements for endocytosis and specific nucleic acid motifs or structures (5). However, the ability to differentiate pathogens from self is only relative, and in the right context, self-nucleic acids, in the form of chromatin, RNA, or RNA–protein complexes, also can activate these receptors (6–13). Herein lies the rub. Certain pathologic conditions may lead to an excess of extracellular self-nucleic acids and nucleic acid–protein complexes, which gain access to the endocytic compartment and activate Toll-like receptors. Thus, endogenous nucleic acids may function as adjuvants and promote autoantibody responses to the TLR ligands themselves (ssDNA and dsDNA), associated proteins (histones and Smith antigen), or nucleic acid–protein complexes (chromatin and small nuclear ribonucleoproteins). In effect, the ligand specificity of the innate immune receptors dictates the antigen specificity of the autoantibody response.

A similar mechanism may promote rheumatoid factor production in the setting of autoimmune diseases and infections. Rheumatoid factor production can be elicited by immune complexes that contain IgG and chromatin (14,15). Similarly, in the setting of infection, IgG immune complexes may contain microbial nucleic acids, as has been demonstrated for hepatitis C virus infection (16). Thus, IgG immune complexes that contain either endogenous or exogenous (i.e., viral) nucleic acids may promote rheumatoid factor production and cryoglobulinemia (17). In addition, such immune complexes that contain TLR agonist activity also may promote local inflammation at the site of immune complex deposition (17).


   Infectious Triggers to Autoimmunity
Top
 Introduction
 Why Nuclear Autoantigens?
 Infectious Triggers to...
Conclusion
 References
 
Infections commonly are associated with low levels of transient autoantibodies and autoreactive T cells (18–21). This suggests that the vast majority of us experience subclinical and transient loss of self-tolerance during infections, when the innate and adaptive immune responses are highly activated. In this issue of the JASN, Pawar et al. (1) use the MRLlpr/lpr mouse model of lupus to demonstrate that activation of the innate immune system in genetically predisposed individuals can trigger disease onset. The studies of Pawar et al. establish that stimulation with CpG DNA, a specific agonist for TLR-9, induces disease in mice with a lupus-prone genetic background. Other TLR agonists tested include poly-I:C, a synthetic dsRNA agonist for TLR-3, and imiquimod, a small molecule agonist for TLR-7; neither of these agonists was capable of inducing lupus in MRLlpr/lpr mice.

A major implication of the findings of Pawar et al. is that CpG DNA and TLR-9 have properties that differ from the other agonists and TLR, and that microbes that are capable of activating TLR-9 may be potent inducers of SLE. The ability of CpG DNA to induce lupus was multifactorial and correlated with its superior ability to induce B cell IL-12p40, B cell proliferation, anti-dsDNA antibodies, and type I IFN (1). The selectivity for CpG is a bit surprising, given the overlap in signaling properties and biologic activities for these TLR. All of these receptors are capable of inducing type I interferons, which have been linked closely to autoimmune disease and lupus in particular (22), suggesting that activation of type I IFN pathway is not sufficient to induce disease. TLR-3 is the most different among these receptors in terms of signaling and cellular distribution, yet TLR-7 and TLR-9 share many similarities in signaling and cellular distribution (4). Both TLR-7 and TLR-9 are expressed on B lymphocytes, a critical feature for the induction of nucleic acid–specific autoantibodies; however, Pawar et al. (1) found that only CpG DNA was capable of potent activation of B lymphocyte proliferation and anti-dsDNA IgG2a.

Other model systems have demonstrated that TLR-9 contributes to the production of specific autoantibodies, but, in contrast to the findings of Pawar et al., TLR-9 has been found to protect against the development of lupus nephritis (6,23–25). One clear difference between these studies and those of Pawar et al. is that the former studies focused on endogenous agonists of TLR-9, whereas Pawar et al. examined the activation of TLR-9 with an exogenous agonist. Therefore, many factors, such as the nature and the dosage of the agonist, timing of exposure, and genetic background, are likely to influence disease.

Testing different agonists, including endogenous or infectious agonists, dosages, and model systems, may unveil roles for other nucleic acid–specific TLR. In fact, recent studies in other model systems support a role for TLR-7 in the generation of autoantibodies and lupus nephritis (24,26). In addition, the y-linked autoimmune accelerating (yaa) locus has been mapped to a translocation and duplication of the TLR-7 locus, indicating that gene dosage and expression of TLR-7 also can contribute to SLE (27,28).


   Conclusion
Top
 Introduction
 Why Nuclear Autoantigens?
 Infectious Triggers to...
 Conclusion
References
 
Pawar et al. (1) make an important contribution to the concept that exogenous stimuli may induce autoimmune diseases and that these function through activating specific innate immune pathways. This study also adds to the authors’ earlier studies that demonstrated that activation of the innate immune system with nucleic acid–specific agonists augments lupus nephritis in mice with established disease (29–32). It will be interesting to see how these findings apply to other autoimmune and acquired diseases, in which self-tolerance, graft tolerance, and inflammation may be modulated by secondary environmental influences.


   Acknowledgments
 
I am supported by National Institutes of Health grants AI062859 and AI052286.


   Footnotes
 
Published online ahead of print. Publication date available at www.jasn.org.

See the related article, "Ligands to Nucleic Acid-Specific Toll-Like Receptors and the Onset of Lupus Nephritis," on pages 3365–3373.


   References
Top
 Introduction
 Why Nuclear Autoantigens?
 Infectious Triggers to...
 Conclusion
 References
 

  1. Pawar RD, Patole PS, Ellwart A, Lech M, Segerer S, Schlondorff D, Anders HJ: Ligands to nucleic acid–specific Toll-like receptors and the onset of lupus nephritis. J Am Soc Nephrol 17 : 3365 –3373, 2006[Abstract/Free Full Text]
  2. Krug A, French AR, Barchet W, Fischer JA, Dzionek A, Pingel JT, Orihuela MM, Akira S, Yokoyama WM, Colonna M: TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 21 : 107 , 2004[CrossRef][Medline]
  3. Meylan E, Tschopp J: Toll-like receptors and RNA helicases: Two parallel ways to trigger antiviral responses. Mol Cell 22 : 561 , 2006[CrossRef][Medline]
  4. Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell 124 : 783 , 2006[CrossRef][Medline]
  5. Barton GM, Kagan JC, Medzhitov R: Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol 7 : 49 , 2006[CrossRef][Medline]
  6. Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, Shlomchik MJ: Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 202 : 321 , 2005[Abstract/Free Full Text]
  7. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, Chang B, Duramad O, Coffman RL: Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 202 : 1131 , 2005[Abstract/Free Full Text]
  8. Boule MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR: Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med 199 : 1631 , 2004[Abstract/Free Full Text]
  9. Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD: Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 115 : 407 , 2005[CrossRef][Medline]
  10. Vollmer J, Tluk S, Schmitz C, Hamm S, Jurk M, Forsbach A, Akira S, Kelly KM, Reeves WH, Bauer S, Krieg AM: Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 202 : 1575 , 2005[Abstract/Free Full Text]
  11. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S: Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303 : 1526 , 2004[Abstract/Free Full Text]
  12. Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ, Christensen SR, Shlomchik MJ, Viglianti GA, Rifkin IR, Marshak-Rothstein A: RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 202 : 1171 , 2005[Abstract/Free Full Text]
  13. Savarese E, Chae OW, Trowitzsch S, Weber G, Kastner B, Akira S, Wagner H, Schmid RM, Bauer S, Krug A: U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 107 : 3229 , 2006[Abstract/Free Full Text]
  14. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A: Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416 : 603 , 2002[CrossRef][Medline]
  15. Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A: Activation of autoreactive B cells by CpG dsDNA. Immunity 19 : 837 , 2003[CrossRef][Medline]
  16. Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, Couser WG, Corey L, Wener MH, Alpers CE, Willson R: Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 328 : 465 , 1993[Abstract/Free Full Text]
  17. Smith KD, Alpers CE: Pathogenic mechanisms in membranoproliferative glomerulonephritis. Curr Opin Nephrol Hypertens 14 : 396 , 2005[Medline]
  18. Wucherpfennig KW: Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest 108 : 1097 , 2001[CrossRef][Medline]
  19. Recher M, Lang KS: Innate (over)immunity and adaptive autoimmune disease. Curr Top Microbiol Immunol 305 : 89 , 2006[Medline]
  20. von Herrath MG, Fujinami RS, Whitton JL: Microorganisms and autoimmunity: Making the barren field fertile? Nat Rev Microbiol 1 : 151 , 2003[CrossRef][Medline]
  21. Kamradt T, Goggel R, Erb KJ: Induction, exacerbation and inhibition of allergic and autoimmune diseases by infection. Trends Immunol 26 : 260 , 2005[CrossRef][Medline]
  22. Banchereau J, Pascual V: Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25 : 383 , 2006[CrossRef][Medline]
  23. Lartigue A, Courville P, Auquit I, Francois A, Arnoult C, Tron F, Gilbert D, Musette P: Role of TLR9 in anti-nucleosome and anti-DNA antibody production in lpr mutation-induced murine lupus. J Immunol 177 : 1349 , 2006[Abstract/Free Full Text]
  24. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ: Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25 : 417 , 2006[CrossRef][Medline]
  25. Yu P, Wellmann U, Kunder S, Quintanilla-Martinez L, Jennen L, Dear N, Amann K, Bauer S, Winkler TH, Wagner H: Toll-like receptor 9-independent aggravation of glomerulonephritis in a novel model of SLE. Int Immunol 18 : 1211 , 2006[Abstract/Free Full Text]
  26. Berland R, Fernandez L, Kari E, Han JH, Lomakin I, Akira S, Wortis HH, Kearney JF, Ucci AA, Imanishi-Kari T: Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice. Immunity 25 : 429 , 2006[CrossRef][Medline]
  27. Subramanian S, Tus K, Li QZ, Wang A, Tian XH, Zhou J, Liang C, Bartov G, McDaniel LD, Zhou XJ, Schultz RA, Wakeland EK: A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci U S A 103 : 9970 , 2006[Abstract/Free Full Text]
  28. Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S: Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312 : 1669 , 2006[Abstract/Free Full Text]
  29. Pawar RD, Patole PS, Zecher D, Segerer S, Kretzler M, Schlondorff D, Anders HJ: Toll-like receptor-7 modulates immune complex glomerulonephritis. J Am Soc Nephrol 17 : 141 , 2006[Abstract/Free Full Text]
  30. Patole PS, Grone HJ, Segerer S, Ciubar R, Belemezova E, Henger A, Kretzler M, Schlondorff D, Anders HJ: Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J Am Soc Nephrol 16 : 1326 , 2005[Abstract/Free Full Text]
  31. Anders HJ, Banas B, Schlondorff D: Signaling danger: Toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 15 : 854 , 2004[Abstract/Free Full Text]
  32. Anders HJ, Vielhauer V, Eis V, Linde Y, Kretzler M, Perez de Lema G, Strutz F, Bauer S, Rutz M, Wagner H, Grone HJ, Schlondorff D: Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J 18 : 534 , 2004[Abstract/Free Full Text]

Related Article

Ligands to Nucleic Acid–Specific Toll-Like Receptors and the Onset of Lupus Nephritis
Rahul D. Pawar, Prashant S. Patole, Andreas Ellwart, Maciej Lech, Stephan Segerer, Detlef Schlondorff, and Hans-Joachim Anders
J. Am. Soc. Nephrol. 2006 17: 3365-3373. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2006101138v1
17/12/3273    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, K. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, K. D.
Related Collections
Right arrowRelated Article

HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP